The US is the bigger Oncology/Cancer Drugs market: $74.3 Bn against $3.2 Bn in 2023, about 23 times as large.
India grows faster: 11.4% a year, against 6.4%. The gap still grows from $71.1 Bn to $128.8 Bn by 2033.
Clinical research: 9,188 active trials in the US, 272 in India.
| Measure |  US |  India |
|---|---|---|
| Market size, 2023 | $74.3 Bn | $3.2 Bn |
| Market size, 2033 projected | $138.2 Bn | $9.5 Bn |
| Growth a year (CAGR) | 6.4% | 11.4% |
| Money added, 2023–2033 | $63.9 Bn | $6.3 Bn |
| Share of the world market | 42% | 1.8% |
| Size rank of 24 countries | #1 | #12 |
| Market per person, 2023 | $218 | $2.20 |
| Active clinical trials | 9,188 | 272 |
| Full report | US report | India report |
Year by year, 2023 to 2033
US India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Oncology/Cancer Drugs, US or India?
The US is the bigger Oncology/Cancer Drugs market: $74.3 Bn against $3.2 Bn in 2023, about 23 times as large.
Which grows faster in Oncology/Cancer Drugs, US or India?
India grows faster: 11.4% a year, against 6.4%. The gap still grows from $71.1 Bn to $128.8 Bn by 2033.
More Oncology/Cancer Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.